Inventor

NAKAMURA KAZUYASU

JP68 patents

⚠️ This page may combine multiple inventors who share the name “NAKAMURA KAZUYASU”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

NAKAMURA KAZUYASU

KYOWA HAKKO KOGYO KK

Antibody composition-producing cell

Mammalian host cell modified by RNAi to inhibit α 1,6-fucosyltransferase

Method of modulating the activity of functional immune molecules

Cells producing antibody compositions with increased antibody dependent cytotoxic activity

Antibody against human interleukin-5-receptor α chain

Recombinant antibody and antibody fragment

Humanized antibodies to ganglioside GM2

Anti-human VEGF receptor Flt-1 monoclonal antibody

Human CDR-grafted antibody and antibody fragment thereof

Humanized antibodies

Humanized antibodies

Recombinant antibody against human insulin-like growth factor

Antibody against human insulin-like growth factor

Method of treating atopic dermatitis using antibody against human interleukin-5 receptor alpha chain

Method of treatment by administering an antibody to human interleukin-5 receptor α chain

Antibody against human interleukin-5 receptor alpha chain

Humanized antibodies to ganglioside GM2

Humanized antibodies to ganglioside GM2

Anti-human VEGF receptor FLT-1 monoclonal antibody

Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3

Methods using eosinophil-specific apoptosis inducer

DNA encoding humanized antibodies specific for the ganglioside GM2

KYOWA HAKKO KIRIN CO LTD

Antibody composition-producing cell

Methods for producing antibody compositions with increased ADCC

Method of modulating the activity of functional immune molecules to CD52

Antibody composition-producing cell in which enzyme expression is inhibited by RNAi

Method of modulating the activity of functional immune molecules to platelet-derived growth factor receptor

Antibody composition exhibiting increased cellular cytotoxicity due to glycosylation

Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein

Method of modulating the activity of functional immune molecules

Method of modulating the activity of functional immune molecules to Her-2

Method of modulating the activity of functional immune molecules to CXCR4 protein

Method of modulating the activity of functional immune molecules

Method of modulating the activity of functional immune molecules to GM2

Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation

Human CDR-grafted antibody and antibody fragment thereof

Method for treating Th2-mediated disease

Method of modulating the activity of functional immune molecules

Antibody composition-producing cell

Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor

KANDA YUTAKA

Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase

Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation

Antibody composition-producing cell

Glycoengineered, recombinant antibody

Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody

NAKAGAWA TOMOAKI

Anti-CD4 antibody

NAKAMURA KAZUYASU

Method of enhancing of binding activity of antibody composition to Fcγ receptor IIIa

HANAI NOBUO

Method of modulating the activity of functional immune molecules

SHITARA KENYA

Method for producing recombinant antibody and antibody fragment thereof

OHTA SO

Anti-claudin-4 antibody